CD86 and neoplasm: HIF‐1α, as an important nuclear transcription factor, can promote the expression of immune checkpoint ligands, such as PDL‐1, CD80, and CD86, and lead to immunosuppression at tumor sites.[156] As a result, the effect of nanomedicines can be further increased to promote immunotherapy by normalizing these factors as the next step in research.